| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GILD | Common Stock | Sale | $146,360 | -2,000 | -1.9% | $73.18 | 100,936 | 28 Feb 2024 | Direct | F1 |
| transaction | GILD | Common Stock | Sale | $598,624 | -8,230 | -8.2% | $72.74 | 92,706 | 29 Feb 2024 | Direct | F1, F2, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. |
| F2 | Sale prices reported for the transactions reported here range from $72.454 to $72.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| F3 | Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |